Article Sidebar

Download
PDF (Bahasa Indonesia)
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

Atherosclerosis is a serious condition characterized by the buildup of plaque on artery walls, causing them to narrow and harden, which can impede the flow of oxygen-rich blood throughout the body, leading to heart disease, stroke, or peripheral vascular disease. In the management of atherosclerosis, therapy more than 5 is usually given; this can increase the risk of drug interactions that are often overlooked. Therefore, the purpose of this study was to determine the factors that influence drug interactions. The inclusion criteria for this study were patients diagnosed with atherosclerosis in inpatients and outpatients, receiving therapy for≥5, aged 18-65 years, and willing to participate as research respondents. The exclusion criteria were receiving therapy <5 and patients refusing to be respondents. Data on patient characteristics, therapy, adverse drug reactions (ADRs), and drug interaction events were described descriptively. Data analysis used the Kolmogorov-Smirnov test. The study included 191 patients, predominantly male (54.4%), with comorbidities (65%), anticoagulant and antiplatelet therapy (27.7%), with ADRs of aspirin and clopidogrel in 28 cases and warfarin in 33 cases, and moderate drug interactions (53.4%). The study concluded that demographic factors such as age, gender, therapy, comorbidities, number of medications, and ADRs significantly influenced drug interactions (p=0.000). This suggests that many demographic factors influence the incidence of drug interactions. The clinical implications of this study are that it can serve as input for comprehensive management guidelines, which can be used to address frequently overlooked drug interactions and achieve optimal therapeutic outcomes.

Keywords

Atherosclerosis Demografhic factors Drug interactions

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

I Nengah Satria Wirananda, Program Studi Sarjana Farmasi, Fakultas Kesehatan, Universitas Bumigora

Program Studi Sarjana Farmasi, Fakultas Kesehatan, Universitas Bumigora

Fitri Apriliany, Program Studi Sarjana Farmasi, Fakultas Kesehatan, Universitas Bumigora

Program Studi Sarjana Farmasi, Fakultas Kesehatan, Universitas Bumigora

Novitarinia Novitarinia, Universitas Bumigora

Program Studi Sarjana Farmasi, Fakultas Kesehatan, Universitas Bumigora
How to Cite
Satria Wirananda, I. N., Apriliany, F., & Novitarinia, N. (2026). Analisis Faktor Yang Berpengaruh Terhadap Interaksi Obat Pada Aterosklerosis Di RSUD Provinsi NTB. Borneo Journal of Pharmascientech, 10(2), 181-193. https://doi.org/10.59053/bjp.v10i2.807
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Adondis, J., Mongi, J., Tiwow, G. A. R., & Palandi, R. R. (2019). Studi Potensi Interaksi Obat Pada Pasien Gagal Jantung Di Instalasi Rawat Inap Rumah Sakit Advent Manado. Biofarmasetikal Tropis, 2(2), 124–135. https://doi.org/10.55724/jbiofartrop.v2i2.125
  2. Apriyandi, R. A., Puspitasari, I. M., Putriana, N. A., Farmasi, F., & Padjadjaran, U. (2020). EFEK SAMPING PENGGUNAAN WARFARIN DAN KOMBINASI WARFARIN DENGAN OBAT LAIN Restu. Farmaka, 18(2), 132–145.
  3. Ayu Fajariyani, Tyssa Mariyana, & Patimah Rachamawati. (2024). Kajian Retrospektif Potensi Interaksi Obat Resep Polifarmasi pada Pasien Poli Jantung di Rumah Sakit X Di Karawang. The Journal General Health and Pharmaceutical Sciences Research, 2(2), 08–16. https://doi.org/10.57213/tjghpsr.v2i2.338
  4. Bergström, G., Persson, M., Adiels, M., Björnson, E., & Bonander, C. (2021). Prevalence of Subclinical Coronary Artery. Circulation, 144, 916–929. https://doi.org/10.1161/CIRCULATIONAHA.121.055340
  5. Bestari, M. B., & Joewono, I. R. (2017). Aspirin vs . P2Y12 Inhibitor Rivalry : Which One Should be Continued During Gastrointestinal Bleeding. Indones J Intern Med, 51(3), 282–286.
  6. Dai, D., Fernandes, J., Sun, X., Lupton, L., Payne, V. ., & Berk, A. (2024). Journal of Health Economics Multimorbidity in Atherosclerotic Cardiovascular Disease and Its Associations Evidence Study. Journal of Health Economics and Outcomes Research, 11(1), 75–85. https://doi.org/10.36469/jheor.2024.94710
  7. Dokter, P., & Kardiovaskular, S. (2022). Panduan prevalensi penyakit kardiovaskular aterosklerosis. Perki.
  8. Gosavi, S., Krishnan, G., & Acharya, R. V. (2023). Aspirin vs Clopidogrel : Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed. Cureus, 15(4), 1–9. https://doi.org/10.7759/cureus.37890
  9. Hajar, R. (2017). Risk Factors for Coronary Artery Disease: Historical Perspectives. HEART VIEWS, 18. https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS
  10. Hartayu, T. S. S. (2017). THE EFFECTIVENESS OF CLOPIDOGREL AS AN ANTITHROMBOTIC COMPARED TO TICLOPIDINE AND ASPIRIN ( META-ANALYSIS ) EFEKTIVITAS CLOPIDOGREL SEBAGAI ANTITROMBOTIK DIBANDINGKAN TERHADAP TICLOPIDINE DAN ASPIRIN ( META-ANALYSIS ) Fakultas Farmasi , Universitas Sanata. Jurnal Farmasi Sains Dan Komunitas, 14(1), 65–73.
  11. Hetherington, I., & Totary-Jain, H. (2022). Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations. Molecular Therapy, 30(10), 3106–3117. https://doi.org/10.1016/j.ymthe.2022.08.024
  12. Huang, X., & Song, J. (2025). Understanding Drug Interactions in Antiplatelet Therapy for Atherosclerotic Vascular Disease : A Systematic Review. CNS Neuroscience & Therapeutic, 31, 1–22. https://doi.org/10.1111/cns.70258
  13. Hussain, M. A., Mamun, A. Al, Peters, S. A. E., Woodward, M., & Huxley, R. R. (2016). The Burden of Cardiovascular Disease Attributable to Major Modi fi able Risk Factors in Indonesia. J Epidemiol, 26(10), 515–521. https://doi.org/10.2188/jea.JE20150178
  14. Kam, D. (2023). Cardiovascular Aging : Understanding the Mechanisms and Risks. Open Access Macedonian Journal of Medical Sciences, 12(1000159), 1000159. https://doi.org/10.35248/2261-7434.23.12.159
  15. Kim, M. J., Valerio, C., & Knobloch, G. K. (2023). Potassium Disorders: Hypokalemia and Hyperkalemia. American Family Physician, 107(1), 59–70.
  16. Li, X., Pang, X., Sun, H., Zhang, B., Wang, H., Wu, N., & Yang, L. (2025). Cardiac aging : Molecular mechanisms and therapeutic interventions. Pharmacological Research, 221(June), 107954. https://doi.org/10.1016/j.phrs.2025.107954
  17. Longpré-Poirier, C., Dougoud, J., Moussaoui, F., Vilme, J., Desjardins, G., & Cartier, L. (2022). Sex and Gender and Allostatic Mechanisms of Cardiovascular Risk and Disease. Canadian Journal of Cardiology, 38(12), 1–8. https://doi.org/https://doi.org/10.1016/j.cjca.2022.09.011
  18. Maharani, A., Id, S., Praveen, D., & Id, D. O. (2019). Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia : The SMARThealth Extend study. Pl, 1–13.
  19. Nur’aini; Kuncoro, B., & Yanti, Y. (2019). EVALUATION OF CORONARY HEART DRUG INTERACTIONS IN PATIENTS HOSPITALISED IN TANGERANG GENERAL HOSPITAL 2017. Jurnal Farmagazine, VI(1), 38–46.
  20. Obayashi, Y; Natsuaki, M. et al. (2025). Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment Elevation Editorial. JACC Journals, 4, 1–7. https://doi.org/10.1016/j.jcin.2025.03.029
  21. Oktaviani, i;Setiadi, F. et al. (2024). Potensi interkasi obat pada pasien penyakit jantung koroner akut di rawat inap rumah sakit fatmawati tahun 2023. Jurnal Farmasi Klinik Best Practice, 3(2), 56–70.
  22. Ozturk, M., Ipekci, A., Kusku, S., & Sinem, Y. (2019). Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department. Journal Clin Med Res and Elmer Press Inc, 11(2), 106–113.
  23. Papotti, B., Marchi, C., Pia, M., & Potì, F. (2021). Drug-drug interactions in polypharmacy patients : The impact of renal impairment. Current Research in Pharmacology and Drug Discovery, 2(March), 100020. https://doi.org/10.1016/j.crphar.2021.100020
  24. Rahmawati, D. U., Mutmainah, N., & Surakarta, U. M. (2021). Kajian Interaksi Obat Potensial Pada Pasien Penyakit Jantung Koroner Rawat Inap di RSUD Moewardi Tahun 2018. Urecol, 417–428.
  25. Rasdianah, N., Hiola, F., Mu, A., Suryadi, A., & Wahyuni, A. S. (2021). Interaksi Obat Pada Pasien Diabetes Melitus Tipe 2 Dengan Penyakit Penyerta Di Rumah Sakit Otanaha Kota Gorontalo. Indonesian Journal of Pharmaceutical (e-Journal), 1(1), 39–46. https://doi.org/10.22487/.ijpe.vlil.9953
  26. Reyaan, I. B. M., Kuning, C., & Adnyana, I. K. (2021). Studi Potensi Interaksi Obat Pada Resep Polifarmasi di Dua Apotek Kota Bandung. JMPF, 11(3), 145–152.
  27. Tscharre, M., Mutschlechner, D., Huber, K., & Gremmel, T. (2025). Antiplatelet therapy with clopidogrel versus aspirin in atherosclerotic cardiovascular disease : a systematic review and meta-analysis. Scirnce Direct, 409, 1–6.
  28. Vyas, V., Sankari, A., & Goyal, A. (2024). Acute Pulmonary Embolism. StatPearls NCBI Bookshelf.
  29. Waheed, S. M., Kudaravalli, P., & Hotwagner, D. T. (2023). Deep Venous Thrombosis. StatPearls NCBI Bookshelf.
  30. Wardani, A. k. (2019). EVALUASI DRUG RELATED PROBLEMS (DRPs) KATEGORI PEMILIHAN DOSIS, KONTRAINDIKASI DAN INTERAKSI OBAT PADA KEMOTERAPI KANKER KOLOREKTAL DI INSTALASI RAWAT INAP RSUD DR. MOEWARDI TAHUN 2018. UNIVERSITAS MUHAMMADIYAH SURAKARTA.
  31. Wong, M. Y. Z., Yap, J., Huang, W., Tan, S. ., & Yeo, K. (2021). Impact of Age and Sex on Subclinical Coronary Atherosclerosis in a Healthy Asian Population. JACC, 1(1). https://doi.org/10.1016/j.jacasi.2021.05.002
  32. Yang, Y., & Li, L. (2020). Effects of aspirin and clopidogrel on the clinical efficacy , adverse reactions and prognosis for elderly patients with acute coronary syndrome. Int J Clin Exp Med, 13(6), 4488–4494.
  33. Zahra, F., Satryo, O., Wahyuni, D., Suprapti, B., Nilamsari, W. P., & Alsagaff, M. Y. (2025). Exploring Side Effects of Warfarin in Outpatients at Tertiary Hospital in Indonesia. Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia, 12(2), 142–150. https://doi.org/10.20473/jfiki.v12i22025.142-150
  34. Zaidi, S. R. R. (2025). Interpretation of Blood Clotting Studies and Values ( PT , PTT ,. StatPearls NCBI Bookshelf.
  35. Zheng, W., Huang, X., Wang, X., Suo, M., Yan, Y., Gong, W., Ai, H., Que, B., & Nie, S. (2024). Impact of multimorbidity patterns on outcomes and treatment in patients with coronary artery disease. European Heart Journal Open, 4(2), 1–8. https://doi.org/10.1093/ehjopen/oeae009